ALKERMES | ALKS - Себестоимость





Себестоимость Изменить Дата
AbbVie USD 4.29B 73M 2026-06
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
ALKERMES USD 120.7M 47.44M 2026-06
Amgen USD 1.87B 271M 2026-06
Biogen USD 945.1M 147.6M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.27B 309M 2026-06
Gilead Sciences USD 1000M 445M 2026-06
Heron Therapeutics USD 11.12M 795K 2025-12
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
J&J USD 8B 67M 2026-06
Merck USD 3.14B 200M 2026-06
Minerva Neurosciences 386K 31K 2024-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Otsuka Holdings JPY 191.82B 17.73B 2026-06
Pfizer USD 4.09B 498M 2026-06
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06